The new technologies of radionuclide therapy are allowing for personalized treatment of various forms of cancer. Learn more about the clinical utility of these procedures and earn free CE credit.
Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.
Molecular imaging is a type of medical imaging that provides detailed pictures of what is happening inside the body at the molecular and cellular level. Where other diagnostic imaging procedures—such as x-rays, computed tomography (CT) and ultrasound—offer pictures of physical structure, molecular imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes.
Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radiopharmaceuticals are detected by special types of cameras that work with computers to provide very precise pictures of the area of the body being imaged. Nuclear medicine can also be used to treat certain types of cancer and other diseases.
Molecular imaging offers unique insights into the human body that enable physicians to personalize patient care. In terms of diagnosis, molecular imaging is able to:
SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.
The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:
SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2015-2017 SNMMI Wagner-Torizuka Fellowship.
On Wednesday, August 26, SNMMI submitted comments to CMS on the CY 2016 Proposed Rules for the Hospital Outpatient Prospective Payment System (HOPPS) and the Medicare Physician Fee Schedule (MPFS).
(Government Relations News)
Researchers have discovered that PET imaging with a specific biomarker can detect a fast-growing primary prostate cancer and is better able to differentiate it from benign prostate lesions, a process that they hope could eventually replace the traditional ultrasound-guided 12-core biopsy.
(MI: Making a Difference)
PET/CT is a valuable tool in the staging of cancer and monitoring of treatment response in patients. However, the appearance and apparent uptake of small lesions in particular, such as liver metastases and lung nodules, can vary significantly depending on the choice of reconstruction algorithm and parameters.
(MI: Making a Difference)
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the National Cancer Institute (NCI) held a joint workshop—NCI-SNMMI Workshop on Targeted Radionuclide Therapy—on October 24-25, 2014, at the National Institutes of Health (NIH) in Bethesda, Md.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.